“Global Research Antibodies Market is anticipated to surpass USD 3 billion by 2020”, says Visiongain

07 November 2019
Pharma

Visiongain has launched a new pharma report “Research Antibodies Market Report” Prospects by Application (Infectious Diseases, Immunology, Oncology, Stem cells, Other applications), Product (Reagents, Antibodies), End use (Academic & Research Institutes, Contract Research Organizations, Pharmaceutical & Biotechnological Companies) and Geography.

The global research antibodies market is projected to grow on account growing stem cells and neurobiology research, and increasing investment in R&D. The global market is projected to grow at a lucrative CAGR of ~6% over the forecast period 2020-2030 and anticipated to surpass USD 3 billion by 2020.

The key drivers of the research antibodies market are growing R&D activities, expenditure in the life science sector, increasing funding for drug discovery and proteomics research, and increasing collaboration between industries and academic institutes. However, the quality concerns regarding research antibodies in terms of research reproducibility, costly and time-consuming processes of antibody production, and the price pressures faced by major market players are the major challenges currently at stake on the market.

Growing cancer prevalence and other chronic diseases also stimulate academic institutions as well as pharmaceutical and biotechnology companies to develop new treatments and personalized medicines. This is one of the key market growth trends. In the medical industry, the use of experimental antibodies throughout early cancer detection has also gained a lot of recognition.

Thanks to the unprecedentedly growing population affected by cancer, oncology was the leading application category in 2018. According to WHO, in the coming years, the number of new cancer cases is likely to rise by over 70%. Moreover, cancer is the second leading cause of mortality rates, encouraging strong medical urgency to improve cancer research & diagnosis.

During the forecast period, the stem cell segment is projected to witness an exponential growth rate. Research Aid for specific and live immune cell staining of various stem cells such as adult, embryonic, and pluripotent stem cells. Also, technologies for cell isolation and cell culture are expected to promote the segment's growth prospects.

North America, led by Europe, accounted for the largest share of the market for research antibodies in 2018. This geographic segment shows significant market growth opportunities owing to growing proteomics and genomics research activities, favorable government funding initiatives, and stakeholder emphasis on research projects.

Over the forecast period, Asia Pacific is expected to post a remarkable CAGR. Increasing progress in the production of antibodies is expected to be responsible for new growth avenues across the world. Furthermore, to stimulate regional market growth, there is a need for improvement of healthcare infrastructure coupled with the strengthening of favorable regulatory policies implemented by public healthcare organizations to improve safety is expected.

Some of the major players operating in this industry are Abcam PLC, Agilent Technologies, Inc., Becton, Dickinson and Company, Biolegend, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Genscript, Lonza, Merck Group, Perkinelmer, Inc., Thermo Fisher Scientific Inc., Sanofi, Amgen, AbCellera Biologics Inc., and Teva Pharmaceutical Industries Ltd among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever